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Abstract
Biobanks have evolved, and their governance procedures have undergone important trans-
formations. Our paper examines this issue by focusing on the perspective of the profession-
als working in management or scientific roles in research-based biobanks, who have an
important impact on shaping these transformations. In particular, it highlights that recent
advances in molecular medicine and genomic research have raised a range of ethical, legal
and societal implications (ELSI) related to biobank-based research, impacting directly on
regulations and local practices of informed consent (IC), private-public partnerships (PPPs),
and engagement of participants. In our study, we investigate the ways that these concerns
influence biobanking practices and assess the level of satisfaction of the cross-national bio-
banking research communities with the ELSI related procedures that are currently in place.
We conducted an online survey among biobankers and researchers to investigate second-
ary use of data, informing and/or re-contacting participants, sharing of data with third parties
from industry, participant engagement, and collaboration with industrial partners. Findings
highlight the need for a more inclusive and transparent biobanking practice where biobanks
are seen in a more active role in providing information and communicating with participants;
the need to improve the current IC procedures and the role of biobanks in sharing of sam-
ples and data with industry partners and different countries, and the need for practical, tangi-
ble and hands-on ethical and legal guidance.
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Introduction
The European biobank landscape has experienced extensive growth and change over the last
few decades [1–3]. Not only have the number of biobanks multiplied [1, 4] but the understand-
ing of what constitutes a biobank has changed. Defined originally as mere ‘collections of sam-
ples and tissues’ [4] and ‘associated data’ [5–8], biobanks have evolved into complex
infrastructures, which contribute in important ways to health research and operate at national,
regional and global levels [9, 10]. This development, together with current advances in molecu-
lar medicine and genomics, has led to ethical, legal and societal implications (ELSI) related to
three main areas of concern.
First, biobanks participants and stakeholders are in demand of greater transparency regard-
ing the use and sharing of health data for research [11]. Transparency is required not only at
the time of collection of the informed consent, but throughout the whole research process [12,
13]. There is increasing encouragement for feedback of research results to biobank participants
[14, 15]. Transparency about the generation and managing of research data with possible
health utility for research participants is vital in order for biobanks to develop ethically robust
policies to cater for this facility.
Second, and related to the first, biobank participants, initially often viewed as simple
‘donors’ who allowed their sample to be used, are now becoming ‘participants’, ‘partners’, or
even ‘stakeholders’ as a recognition of their active involvement in the biobank’s activities
including research [2, 16]. There is growing understanding that participant engagement is
essential in order to increase attention rates, maintain retention rates, build trust in the
research, improve its relevance and utility, and enable continuous data collection to inform
future research projects [17].
Third, publicly-funded biobanks are increasingly encouraged to develop partnerships with
industrial actors such as pharmaceutical companies and biotechnology start-ups, to accelerate
research discovery and promote the advancement of personalized medicine [18, 19]. Public-
private partnerships (PPPs) impact established practices related to human biological speci-
mens as well as health research-related data processing and sharing across biobanks and coun-
tries [19]. Studies show how collaborations with industry, envisioned to benefit science and
society, must be further assessed in view of ELSI challenges such as conflicts of interests and
questions around profit-based activities versus public health activities [18].
Many studies on biobanking have explored public attitudes towards ELSI challenges of bio-
banking [20–22] and have identified a need to involve participants in defining the consent pro-
cess related to data processing [23], as well as a need to engage citizens in the related public
discussion on biobanking [24]. Little has been done, however, to investigate the views of pro-
fessionals in the field of biobanking regarding the ELSI challenges of biobanking. The needs
related to biobank-based research have changed in the last past few years with increasing
importance of ongoing of study participants, whether to contribute new data, to move into
translational approaches or to support existing studies. The views of biobank professionals on
participatory approaches play a major role in this respect and have not been closely explored
to date. This paper contributes to fill this lacuna. Here, we report and discuss findings from a
large online survey investigating the views of biobankers and researchers in relation to these
three key issues.
Furthermore, the introduction of two recent major legal instruments has impacted directly
on the issues under scrutiny here: 1) the European Union General Data Protection Regulation
2016/679 (GDPR) lays out new requirements in terms of transparency, data subjects’ rights,
and information about data uses [25], and introduces the principles of accountability and
direct responsibility of the processor towards the subject; 2) the Article 27 of The Additional
Data in question
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Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical
Research, establishes a duty of care in the countries that have ratified this Council of Europe
instrument. Both these legal instruments have been shaping the ways the biobank community
has understood its challenges and aims, and they create a core context to the interpretation of
our survey, conducted just 10 weeks before GDPR and the Article 27 went into force. Although
our survey was not designed as an analysis of implementation of GDPR, much less for making
conclusions about the attitudes of biobankers towards this new and important legal landscape,
the GDPR has indeed constituted the stage of reflection of current biobank governance.
Viewed from that perspective, the GDPR impacts our survey by constituting an opportunity
for research institutions and biobanks to adapt to these new legal frameworks, while laying out
provisions and exceptions expressly thought of in the context of research.
Against this background, we asked biobankers and researchers to evaluate the issues of (1)
participant information concerning enrolment, re-contact, and secondary use of data, (2) par-
ticipant engagement, and (3) collaboration and sharing of data with industrial partners. This
paper presents the experiences and opinions of 273 biobankers from 32 countries. After outlin-
ing our research design and methods, we discuss our data and flag resulting implications
related to participant engagement and the everyday practice of biobanking.
This survey was conducted as a key task of BBMRI-ERIC, a research infrastructure for bio-
banks and biomolecular resources [26] that systematically scans the horizon for upcoming
debates and questions surrounding ethical, legal, and societal aspects of biobanking, and pro-
vides professional support to biobanks through the Common Service ELSI [27] (http://www.
bbmri-eric.eu/BBMRI-ERIC/about-elsi/) as well as the H2020 project ADOPT BBMRI-ERIC
(http://www.bbmri-eric.eu/scientific-collaboration/adopt-bbmri-eric/), and the COST Action
IS1303 CHIP ME (http://www.cost.eu/COST_Actions/isch/IS1303). Collaborators were the
FP7 project RD-connect (https://rd-connect.eu), the IMI project DO-IT (https://www.imi.
europa.eu/projects-results/project-factsheets/do-it) and Biobank Norway (https://www.ntnu.
edu/biobanknorway). These projects and organizations have enabled discussions about bio-
bank related issues across countries and disciplines.
Methods
Study design and participant recruitment
This study was driven by the key research question: how do the current changes related to the
ethical, legal, societal and scientific landscape of biobanking impact on attitudes, beliefs and
practices in the sector? Based on the hypothesis that ethical, legal and societal challenges, man-
ifested in different local practices of IC, private-public partnerships, and engagement of partic-
ipants are affecting the use of biobanks, we investigated both professional experiences and
opinions about (1) secondary use and sharing of data and collaboration with industrial part-
ners and (2) informing and/or re-contacting participants with a special focus on participant
engagement.
The survey was sent to experts with experience as researchers or other professional activities
related to biobanks and/or collections of biological samples. These inclusion criteria were con-
firmed in the survey. Along with the IC of respondents, these were necessary to start the online
questionnaire. The link to the survey was disseminated primarily through the BBMRI-ERIC e-
newsflash (approximately 6,000 subscribers), the BBMRI-ERIC Directory (https://directory.
bbmri-eric.eu) (approximately 600 biobanks and collections), the BBMRI National Nodes net-
works, and the newsletters of the partners of this study. Associated organizations were also
asked to further circulate the survey link. Additionally, the survey was promoted through vari-
ous social media channels including @bbmrieric, @corbel, Twitter, and LinkedIn. Recruitment
Data in question
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was carried out in two waves. First, the survey was widely promoted through the channels out-
lined previously. Second, recruitment was intensified in countries that were underrepresented
one month before the survey closed. The survey was open between December 2017 and March
2018.
Data was collected via an online survey and administered using SurveyMonkey.com. Our
research question was operationalised by collecting data on 116 items within 25 multiple
choice questions. The survey was divided into four sections. The first collected information
about the characteristics of the biobanks (type of collections, major source of funding, respon-
dents’ position). The remaining questions were organized under three topics, where respon-
dents were asked to provide answers regarding their experiences with, and opinions about IC,
participant involvement, and public-private partnerships. Response options were derived from
recent scientific literature discussed throughout the paper debating secondary use of data,
informing and/or re-contacting participants, sharing of data with third parties from industry,
participant engagement, and collaboration with industry partners. Items compiling details
about what information is and should be provided in the IC procedure were selected in line
with GDPR requirements. Open-ended answer fields were included to allow collection of
more in-depth qualitative data. The questionnaire was pre-tested with potential respondents
from the target group to evaluate comprehensiveness, length, and clarity, and was refined
accordingly (see survey instrument in S1 File).
Data analysis focused on the following topics: (1) the content of the IC documents in use,
identifying areas where the related IC procedure is considered by the biobankers using it to be
lacking; (2) the state of play with regards to re-use of samples and associated re-consent,
exploring attitudes on how these aspects should be managed within the IC document; (3) the
level of data-linkage and data-sharing within respondents’ current biobanking practices; (4)
the perceived need for professional legal and ethical support resources and (5) the state of play
with regards to participant engagement and health industry stakeholder engagement.
Correlations were tested using the Pearson Chi-Square test in SPSS and values of p<0.05
were considered statistically significant. Responses to questions allowing open-ended answers
were analysed thematically, in line with standards of qualitative research methodology.
Responses were analysed for recurring topics as well as issues raised which were not covered
by the given answer options. Themes arising from the answers were identified.
For legal data analysis purposes, questions concerning practices of and attitudes towards
IC, participant involvement and public-private collaborations were divided into two groups
depending on whether or not the respondent was based in a country where the GDPR applies.
Country distribution was based the location of the biobank or research facility, as described by
the respondent. Similarly, questions concerning return of results to research participants, were
divided into three groups depending on the country’s relationship with the Additional Proto-
col to the Convention on Human Rights and Biomedicine concerning Biomedical Research
(CETS No. 195).
Ethics statement
Ethics approval for this survey was given by the Research Ethics Committee of the University
of Milano–Bicocca. Electronic IC was given to study participants at the beginning of the online
questionnaire. Respondents were informed about the research scope and type of research, that
their answers would be confidential, and that the results of the survey would be presented in a
way that avoids the identification of individual participants. Respondents gave their IC by tick-
ing a checkbox to confirm that they understood the information provided to them and volun-
tarily agreed to participate in the survey. Re-contact for further studies and interviews would
Data in question
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only be possible if the participants voluntarily provided contact details by following a link to a
separate contact form that was not part of the survey.
Results
Respondents’ demographics
A total of 273 (263 from Europe, 10 from other countries) people completed the survey,
although it was started by 400 people. This relatively high incompletion rate could be due to
recipients believing, once beginning the survey, that they have insufficient knowledge of the IC
procedure in the biobank or research facility in which they are based.
Respondents represent various roles and types of biobanks (see Table 1), and work across a
total of 32 countries. Of these, the majority of respondents’ biobanks or research facilities are
based in Italy (18.3%), followed by the Netherlands (13.9%), Switzerland (8.8%), and the
United Kingdom (7.3%). Twelve countries are represented by a single respondent, 11 by
between two and 10 respondents, and the remaining five are represented by between 11 and
19 respondents each. Well over half of respondents work in publicly financed biobanks,
including both national and regional investments (59.6%), around a quarter of the biobanks
are both publicly and privately financed (26.2%), while the remainder are privately financed
(8.2%) or unknown by the respondent (17.6%).
The majority of respondents are biobankers or researchers from countries which adhere to
the GDPR. These are Austria, Belgium, Bulgaria, Croatia, the Czech Republic, Denmark, Esto-
nia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Malta, the Netherlands, Nor-
way, Poland, Portugal, Spain, Sweden, and the United Kingdom. Respondents from countries
where the GDPR does not apply include Antigua and Barbuda, Bolivia, Canada, Russia, Saint
Barthelemy, Switzerland, Turkey, Ukraine, the United Arab Emirates, and the United States.
Respondents from the three subgroups that were built to analyse answers to questions con-
cerning the return of results to research participants belonged to: (1) countries where the
Table 1. Respondents’ main role related to biobanks and types of biobanks.
Main role of respondent related to biobanks n %
Director/CEO/Manager 88 31.3%
Researcher 69 24.6%
Project manager 46 16.4%
ELSI consultant 33 11.7%
Administrative staff 27 9.6%
Clinician/Researcher 20 7.1%
Clinician 3 1.1%
Technical support 3 1.1%
Business and innovation support/consultant 3 1.1%
Genetic counsellor 1 0.4%
Type of biobank referred to
Prospective disease-oriented biobank 146 51.6%
Biobank or tissue archive containing tissue/specimens leftover from health care interventions
(‘residual use’)
124 43.8%
Population-based biobank (prospective population-based cohort) 99 35.0%
Biobank containing tissue/specimens leftover from specific research projects 98 34.6%
Genetic biobank 76 26.9%
Multi-purpose hospital-based biobank 5 1.8%
Biobank of veterinary resources 2 0.7%
https://doi.org/10.1371/journal.pone.0221496.t001
Data in question
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Additional Protocol to the Convention on Human Rights and Biomedicine concerning Bio-
medical Research is in force (Bulgaria, Hungary, Norway, Portugal, and Turkey), (2) countries
which have signed, but not ratified the Additional Protocol (Denmark, Greece, Italy, Sweden,
and the Ukraine), and (3) countries which have neither signed nor ratified the Additional Pro-
tocol (Antigua and Barbuda, Austria, Belgium, Bolivia, Canada, Croatia, the Czech Republic
(note: the Czech Republic has signed, but not ratified the Additional Protocol after the survey
had closed), Estonia, Finland, France, Germany, Latvia, Malta, the Netherlands, Poland, Rus-
sia, Saint Barthelemy, Spain, Switzerland, United Arab Emirates, the United Kingdom, and the
United States).
Informed consent
A key focus of the survey was to investigate the IC procedures in biobanks and biobank-based
research. Needing samples and data for their research, respondents were asked both what
information is provided by their IC, and what information they believe should be provided by
the IC. Both sets of results are outlined in the following tables.
Table 2 lists 16 items which respondents assessed in terms of what ‘is provided’ and ‘is not
provided’ in the current IC procedure in use in their organisation. Respondents were able to
tick multiple responses.
Survey results show that there are four items which are present in the vast majority of all
ICs. This is consistent with what is expected, with 89.7% of participants including ‘the right to
withdraw IC at any time, and what happens to data and samples afterwards’; 88.8% including
‘the purpose and (future) objectives of the associated research’, 85.7% including ‘general infor-
mation of the biobank and who is responsible for the IC procedure’, and 80.2% including ‘the
contact details of the biobank’.
The two items most frequently flagged as being absent from the current IC are ‘details
about research conducted through the biobank (e.g. via an online tool)’, and the right to lodge
a complaint with a supervisory authority (e.g. an ethics commission) including contact info’
with 58.5% and 51.6% of respondents indicating absence of these respectively. Interestingly,
the latter was also the item that respondents were most unsure about, with 14.1% unable to
indicate whether or not it was included in their IC, followed by ‘sharing data/samples with par-
ties in non-EU countries’ with a rate of 10.7%. Table 2 shows a lack of compliance with the
GDPR in some cases in that the consents are not always properly specified or informed.
One theme dominated the data collected in the ‘other’ free text field provided in the IC pro-
cedure. This was the issue of returns to the participant, with both financial compensation
(none) and reimbursement (for reasonable out of pocket expenses) mentioned as being pro-
vided, as well as finer clarification on the ways incidental findings are returned, if severe and
actionable. Some contributions fell under the theme of ‘active participants’, with ‘right to
restrict access’, and ‘details of advantages and disadvantages of participating’ being mentioned.
One respondent mentioned ‘consent is valid after death’ as an item that was included in their
IC procedure, and another that ‘participation/non-participation will not affect their [medical]
treatment’.
Table 3 shows how respondents assessed seven items in relation to what ‘should be pro-
vided’, and what ‘is not essential’ in the IC:
All seven items were selected by at least 69.1% of the respondents. According to respon-
dents, the top three items that ‘should be’ provided include ‘sharing data/samples with other
non-commercial research partners’, flagged by 90.2% of respondents, ‘the purpose and (future)
objectives of the associated research’ (84.8%), and ‘sharing data/samples with commercial and/
or health industry partners’ (83.8%). The option least frequently selected is ‘possibility of
Data in question
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returning individual research results’, chosen by 69% of respondents, with 27.6% stating that
this is not essential for the IC.
There was no significant difference (p>0.05) between countries that do or do not apply the
GDPR in terms of responses to questions about items currently covered by the IC, the infor-
mation that should be covered in the IC, the type of consent currently in place, the possibility
of data-linkage covered in the IC, practices and attitudes towards re-use of samples and data,
participant involvement, and public-private partnerships.
Data from the two questions mentioned above, ‘what information is provided to partici-
pants/donors in the IC procedure?’ and ‘in your opinion, what information should be pro-
vided to participants/donors in the IC?’, were cross tabulated for the six items that coincide to
assess respondents’ levels of satisfaction with the IC in use (Table 4). This analysis was limited
to respondents who identified the items as missing from their current IC. Since respondents
could select more than one option for both questions the percentages may exceed 100%. Out
of the 136 participants who answered both, ‘is not provided’ and ‘should be provided’, 30.9%
flag ‘sharing data/samples with parties in non-EU countries’ as being an issue that is not in
Table 2. What is provided to participants/donors in respondents’ current IC procedures?
What information is provided to participants/donors in the IC procedure? Is provided in the
IC
Is not provided in the
IC
I don’t
know
General info about the biobank and who is responsible for the IC procedure n 186 20 11
% 85.7% 9.2% 5.1%
Contact details of the biobank n 174 30 13
% 80.2% 13.8% 6.0%
The purpose and (future) objectives of the associated research n 191 16 8
% 88.8% 7.4% 3.7%
Details about research conducted through the biobank (e.g. via an online tool) n 72 124 16
% 34.0% 58.5% 7.5%
Possibility for the participant/donor to be re-contacted for additional data/samples n 135 66 13
% 63.1% 30.8% 6.1%
Possibility of returning individual research results n 129 68 14
% 61.1% 32.2% 6.6%
Linkage of data/samples with data from other sources (e.g. registries, national statistics) n 115 78 20
% 54.0% 36.6% 9.4%
Sharing data/samples with other non-commercial research partners n 165 33 18
% 76.4% 15.3% 8.3%
Sharing data/samples with commercial and/or health industry partners n 119 77 20
% 55.1% 35.6% 9.3%
Sharing data/samples with parties in other EU countries n 125 69 20
% 58.4% 32.2% 9.3%
Sharing data/samples with parties in non-EU countries n 110 82 23
% 51.2% 38.1% 10.7%
Expected storage period for data/samples n 119 81 13
% 55.9% 38.0% 6.1%
The right to withdraw IC at any time and what happens to data and samples afterwards n 192 13 9
% 89.7% 6.1% 4.2%
Other rights of participants, e.g. right to access data or right to know how data is processed n 118 75 20
% 55.4% 35.2% 9.4%
The right to lodge a complaint with a supervisory authority (e.g. an ethics commission), including
contact info
n 73 110 30
% 34.3% 51.6% 14.1%
https://doi.org/10.1371/journal.pone.0221496.t002
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their current IC, but should be. This was the most frequently flagged issue that respondents
believed should be addressed. Other common issues include the ‘possibility for participant/
Table 3. What information should be provided to participants/donors in the IC?
In your opinion, what information should be provided to participants/donors in the
IC?
Should be provided in the IC Is not essential in the IC I don’t know
The purpose and (future) objectives of the associated research n 184 32 1
% 84.8% 14.7% 0.5%
Possibility of re-contact by researchers for additional data/sampling n 175 41 2
% 80.3% 18.8% 0.9%
Possibility of returning individual research results n 150 60 7
% 69.1% 27.6% 3.2%
Sharing data/samples with other non-commercial research partners n 194 17 4
% 90.2% 7.9% 1.9%
Sharing data/samples with commercial and/or health industry partners n 181 24 11
% 83.8% 11.1% 5.1%
Sharing data/samples with parties in other EU countries n 172 36 10
% 78.9% 16.5% 4.6%
Sharing data/samples with parties in non-EU countries n 169 39 11
% 77.2% 17.8% 5.0%
https://doi.org/10.1371/journal.pone.0221496.t003
Table 4. Cross tabulation of ’not provided’ with ’should be provided’ in the IC.
Should be provided Total
The purpose and
(future) objectives
of the associated
research
Possibility for the
participant/donor to
be re-contacted for
additional data/
samples
Possibility of
returning
individual
research results
Sharing data/
samples with other
non-commercial
research partners
Sharing data/
samples with
parties in other
EU countries
Sharing data/
samples with
parties in non-
EU countries
Is not
pro-
vided
The purpose and
(future) objectives of
the associated
research
n 3 12 12 13 13 12 15
% 2.2% 8.8% 8.8% 9.6% 9.6% 8.8%
Possibility for the
participant/donor to
be re-contacted for
additional data/
samples
n 48 40 40 54 50 47 64
% 35.3% 29.4% 29.4% 39.7% 36.8% 34.6%
Possibility of
returning individual
research results
n 55 47 25 59 50 51 66
% 40.4% 34.6% 18.4% 43.4% 36.8% 37.5%
Sharing data/samples
with other non-
commercial research
partners
n 27 25 21 22 18 16 33
% 19.9% 18.4% 15.4% 16.2% 13.2% 11.8%
Sharing data/samples
with parties in other
EU countries
n 61 51 43 55 38 37 68
% 44.9% 37.5% 31.6% 40.4% 27.9% 27.2%
Sharing data/samples
with parties in non-
EU countries
n 72 61 51 66 46 42 81
% 52.9% 44.9% 37.5% 48.5% 33.8% 30.9%
Total n 110 100 81 116 95 92 136
X2(25) = 29.78, p = 0.233
https://doi.org/10.1371/journal.pone.0221496.t004
Data in question
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donor to be re-contacted for additional data/samples’, flagged by 29.4% of respondents, and
‘sharing data/samples with parties in other EU countries’, flagged by 27.9%. The issue least fre-
quently considered to be lacking, defined as one that respondents did not think ‘should be pro-
vided’, is ‘the purpose and (future) objectives of the associated research’. Only 2.2% of
respondents indicated that it was not in their IC and that it ‘should be’ provided.
We compared the responses in the crosstabulation table on items that currently are not, but
should be, covered in the IC with the responses in Table 2. There are noticeable differences in
what is considered essential in IC. For instance, 84.8% of respondents consider ‘the purpose
and (future) objectives of the associated research’ to be an important item to include in the IC.
Yet, among those missing this item in their IC, only 2.2% think it should be added. Similarly,
69.1% stated that the ‘possibility of returning individual research results’ should be included in
ICs, but only 18.4% of those who indicated that this item is missing in their IC stated that it
should be included. This difference also exists for ‘sharing data/samples with other non-com-
mercial research partners’, where 90.2% think this information should be provided in ICs
while 16.2% stated that it is not included in their current IC, but should be.
When evaluating the IC procedure currently in use, 50.7% of the respondents stated that
the IC they are using would benefit from some improvements, 43.0% think that the IC is suffi-
cient and 6.3% didn’t know. 38 respondents elaborated on how they thought their IC would
benefit from improvements. When analysed thematically, these contributions fell under three
overarching themes: (1) information included in the IC; (2) clarity of text, and length of the
document; and (3) a need for a dynamic, web-based component. Regarding the former, infor-
mation flagged as lacking in the IC procedure reflect the topics discussed in previous ques-
tions. These include data linking, data sharing, future use of samples, and return of results
(incidental findings). Two issues were new, however. One respondent highlighted the lack of
choice of consent preferences and another the participant’s right to view their personal data.
The latter issue will likely become more prominent as the GDPR raises awareness of partici-
pants’ rights and how to exercise them.
Document style and presentation was indicated as a source of dissatisfaction by four
respondents. They highlighted unwieldy text, technical language and unrealistic length as
issues requiring attention. Having a dynamic, web-based consent procedure was highlighted
as a potential solution to inadequate active involvement by 10 participants. They listed advan-
tages such as flexibility, getting updates on research progress, having an active choice about
which research projects to be involved in, and the ease of withdrawing consent.
Regarding current IC practices, only 9.5% of respondents indicated that participants can
choose their level of involvement (Table 5).
Considering data re-use and re-consent. 50.5% of respondents stated that re-use should be
practiced without re-consent, whereas 33.3% thought participants should be able to choose
their preferences in terms of re-use of data and samples (Table 6).
The type of biobank and role of respondent did not influence views about data re-use and
reconsent (X2(24) = 25.81, p = 0.363). Nevertheless, the most frequent advocates of multiple
Table 5. Sample and data use currently covered by the biobanks’ IC.
Which sample and data use is currently covered by the IC in biobank you are referring to? n %
Data and samples will be used for multiple research projects without re-consent 126 59.7%
Data and samples will only be used for the study for which the participant gave consent 51 24.2%
Participants/donors can choose their consent preferences about what they want to be involved in
(online or paper-based)
20 9.5%
Data can be used without consent because of a statutory exemption 8 3.8%
I don’t know 6 2.8%
https://doi.org/10.1371/journal.pone.0221496.t005
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uses of data without re-consent were directors/CEOs/managers of biobanks (64.9%) and proj-
ect managers (59%). This said, re-consent is seen as necessary when not only the study, but
also the research field changes. 44.4% of respondents stated that re-consent is necessary when
data and samples are used for a study in a different field, whereas 34.4% consider re-consent
unnecessary in that situation (Table 7).
Thematic analysis of respondents’ additional comments emphasised significant change as
an important factor. For instance, most respondents’ comments highlighted the importance of
re-consenting only when there are significant changes related to the purpose of research or to
participant-related implications. These could include participants’ level of involvement, a com-
promised level of anonymity, the possibility of returning findings due to the use of new tech-
nologies, or changes in biobank governance policies.
Participant engagement
50.7% of respondents stated that there are no specific participant engagement activities under-
taken by the biobank they were referring to. When in place, these activities mainly (38.3%)
comprise information meetings (such as open days, public meetings, and science days).
Respondents also defined public engagement as focus groups, surveys to participants, and
web-based forums (Table 8).
The main obstacles biobankers encounter for involving participants were too little time
resources (51%) and too little financial resources (59.5%). Whereas only 17.5% of respondents
indicated a lack of interest as an impediment to participant involvement (Table 9).
This suggests that biobanks are seen to play an active role; not only as mere collections of
samples and data, but as primary drivers for providing information and engaging with
participants.
Preferences for support
69.1% of respondents stated that when seeking information on how to design or improve their
IC, they would seek ethical and legal guidance from professional information centres such as
helpdesks. Additionally, 65.7% indicated that they would turn to national guidance or stan-
dards for IC and/or corresponding templates, 58.8% to international guidance of standards for
IC and/or corresponding templates, and 41.2% to information from within their working
Table 6. Opinions on how re-use should be practiced in biobanks.
In your opinion, how should re-use be practiced in biobanks? n %
Data and samples should be used for multiple research projects without re-consent 97 50.5%
Participants/donors should choose their consent preferences about what they want to be involved in 64 33.3%
Data and samples could be used without consent because they are anonymised 16 8.3%
Data and samples will only be used for the study for which the participant gave consent 15 7.8%
https://doi.org/10.1371/journal.pone.0221496.t006
Table 7. Opinions on re-consent.
In your opinion, when do you think re-consent is required? n %
If data/samples are to be used for a study in a different field 80 44.4%
I don’t think re-consent is necessary 62 34.4%
If new technology requires a change in practices 22 12.2%
If the field changes 13 7.2%
I don’t know 3 1.7%
https://doi.org/10.1371/journal.pone.0221496.t007
Data in question
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environment or colleagues. The remaining respondents either search the internet (17.2%) or
don’t know (2%) (Table 10).
These findings indicate that multiple sources of information are considered when designing
or improving the IC. 17 other respondents shared additional considerations, such as the inclu-
sion of key stakeholders like ethics committees, data protection officers, or patient advocacy
groups.
Of the 207 respondents who answered this question, 73.9% indicated that they would use
templates that follow national or international standards. 50.2% stated that web-based support
such as interactive tools would be appreciated and 46.4% consider online information such as
a web page (Table 11).
Additional comments received for this question hint towards a discrepancy between the
number of publications available and the difficulty in translating the findings into practical
solutions applicable to a local context.
Public private partnerships
47.1% of respondents stated that their biobank has established collaborations with health
industry partners, and 19.2% stated that there are plans to develop collaborations with stake-
holders from the health industry. The results do not significantly differ between biobanks
financed by public investments and biobanks financed by private investments (p>0.05). The
remaining respondents answered either that their biobank had no collaboration with the
industry (23.6%) or plans to collaborate in the future (1.9%) or that they did not know about
any collaboration (8.2%) (Table 12).
Table 8. Biobank participants’ involvement in activities of the biobank.
In which ways are biobank participants/donors involved in activities of the biobank? n %
No specific engagement activities in place 102 50.7%
Information meetings such as open days, public meetings, science days 77 38.3%
Focus groups or workshops to discuss specific aspects of the research 39 19.4%
Surveys to collect data about the participants’ perspectives on specific topics 38 18.9%
Open forums such as online, web-based participant forums 25 12.4%
I don’t know 7 3.5%
Note: The total percentage exceeds 100% because the participants could select more than one option.
https://doi.org/10.1371/journal.pone.0221496.t008
Table 9. Obstacles to participant involvement.
What obstacles for participant/donor involvement have you encountered in relation to your
biobanking activities?
n %
Too little financial resources 119 59.5%
Too little time resources 102 51.0%
No appropriate IT solutions for providing information 54 27.0%
Too little qualified staff 36 18.0%
No interest in involving participants 35 17.5%
Lack of information about findings gained by samples and data 32 16.0%
No obstacles encountered 11 5.5%
I don’t know 12 6.0%
Note: The total percentage exceeds 100% because respondents could select more than one option.
https://doi.org/10.1371/journal.pone.0221496.t009
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62.0% of respondents thought the biobank should explicitly ask for participants’ broad con-
sent for collaborations with the health industry at the time of recruitment (Table 13). This is
consistent with responses to the question about which information should be provided to par-
ticipants/donors in the IC. The vast majority of respondents (83.8%) believed the IC should
include a section to inform participants about the sharing of data and samples with commer-
cial and health industry partners (Table 3). However, this does not always seem to be the case
in practice, with 55.1% of respondents claiming that the sharing of data and samples with com-
mercial and health industry partners is provided in the IC procedure.
20.5% of respondents considered it sufficient to inform the participants about collabora-
tions with industry partners through, for instance, a newsletter or web page (Table 13). A lim-
ited group of respondents (9.5%) deemed it necessary to collect the consent of participants
each time a new collaboration is established with the health industry. Similarly, a limited
group of respondents (8.0%) said biobanks do not need to provide information to participants
about collaborations with the health industry. Further analysis showed, that there is a signifi-
cant larger percentage of participants working in biobanks that collaborate with health indus-
try partners (90.4%) who agree that sharing data with commercial and/or health industry
partners should be provided in the IC, compared to their counterparts who work in biobanks
that do not collaborate with health industry partners (72.9%). No significant differences in
responses were found between publicly and privately funded biobanks.
Data show that respondents largely believe that collaboration with industry may bring a
range of benefits including enabling the development of drugs and therapies (78.1%), increas-
ing knowledge of disease and treatment (67.1%), and facilitating better research (57.1%). To a
Table 10. Preferences of information sources for designing and improving IC.
If you were designing/improving your IC, where would you search for information? n %
Ethical-legal guidance by professional information centres such as help desks for ethical and legal
issues
141 69.1%
National guidance or standards for IC and/or corresponding templates 134 65.7%
International guidance or standards for IC and/or corresponding templates 120 58.8%
Information from within my working environment or ask colleagues 84 41.2%
The internet 35 17.2%
I don’t know 4 2.0%
Note The total percentage exceeds 100% because the respondents could select more than one option.
https://doi.org/10.1371/journal.pone.0221496.t010
Table 11. Preferences for forms of professional ethical and legal support in relation to IC.
Which form/s of professional ethical and legal support in relation to the IC would you appreciate,
if any?
n %
Templates that follow national or international standards for IC 153 73.9%
Web-based support such as interactive tools 104 50.2%
Online information such as a web page 96 46.4%
Help desk 61 29.5%
Training 55 26.6%
I already have sufficient support 20 9.7%
Training or support are not necessary 4 1.9%
I don’t know 5 2.4%
Note: The total percentage exceeds 100% because the respondents could select more than one option.
https://doi.org/10.1371/journal.pone.0221496.t011
Data in question
PLOS ONE | https://doi.org/10.1371/journal.pone.0221496 September 18, 2019 12 / 22
lesser extent, collaborations with health industry are expected to bring additional income to
the biobank (41.0%), result in personal benefits for the biobank participants, for instance in
the form of new drugs (12.9%), or lead to the creation of new jobs (10.0%).
There was, however, a concern among respondents that collaboration with the health
industry may lead to increased focus on commercial profit rather than public health require-
ments (54.5%). This may translate to industrial partners determining the focus of the research
(52.6%). Concerns were also raised about industrial partners earning money through a collab-
oration, while the biobank could get nothing equal in return (33.5%) or become dependent on
private funding (26.3%). It should be noted that 20.6% of respondents considered none of the
listed risks to be likely.
A large majority of respondents (86.4%) stated that solid contracts describing the responsi-
bilities of the partners are important when collaborations are established with partners from
the health industry. 52.9% believed that both parties in the collaboration should be well-aware
of the details of the collaboration while 38.3% thought the partners in the collaboration should
share data and samples as fairly as possible. Less emphasis was placed on the importance of
fairly sharing benefits (35.9%) and risks (15%). Interestingly, 41.7% of respondents thought
the details of the collaboration should be publicly available.
Discussion
This study explores biobankers attitudes and the challenges they face in the context of evolving
legal, ethical, societal and scientific landscapes related to biobanking. The survey data provide
important insights into current practices and attitudes in this context and highlight the diffi-
culties of responding to these changing landscapes. The survey findings provide a framework
to foster debate about appropriate governance structures. This will improve IC procedures and
public/participant engagement in biobanking.
Challenges for informed consent
A key purpose of IC is to provide research participants with sufficient information to enable
them to make an informed decision about the processing of personal data about them in
Table 12. Collaboration between biobank and health industry partners.
Does your biobank collaborate with health industry partners? n %
Yes 98 47.1%
No 49 23.6%
Not yet, but we plan to develop collaborations with stakeholders from the health industry 40 19.2%
No, and we do not plan to do so 4 1.9%
I don’t know 17 8.2%
https://doi.org/10.1371/journal.pone.0221496.t012
Table 13. Preferences on how biobanks should inform research participants about potential or existing collabora-
tions with stakeholders from the health industry.
In your opinion, how should biobanks inform their research participants/donors about potential
or existing collaborations with stakeholders from the health industry?
n %
Biobanks should explicitly ask for participants’ broad consent for collaborations with the health
industry at the time of recruitment
124 62.0%
Biobanks should inform participants once such collaborations take place (e.g. newsletter or web page) 41 20.5%
Biobanks should ask for participants’ consent for each collaboration with the health industry 19 9.5%
Biobanks do not need to inform participants about collaborations with the health industry 16 8.0%
https://doi.org/10.1371/journal.pone.0221496.t013
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biobanking. Transparency regarding data processing is not only a legal obligation given the
GDPR, but also a preference of biobankers, as indicated in Table 3. Consent may also be used
as a legal basis for data processing under the GDPR. 30.9% of respondents flagged that ‘sharing
data/samples with parties in non-EU countries’ is not in their current IC but should be. If con-
sent is used as a basis for transferring data to non-EU countries, the GDPR requires explicit
consent to the transfer as well as the provision of information about the possible risks of such
transfers. Research, especially given developments in genetics, has become heavily dependent
on data sharing. Biobanks are encouraged to provide access to samples and data as well as to
share data for secondary uses with national and international research consortia plus academic
and/or industrial partners. The amount of information they provide to their participants about
secondary use of data in the IC is nevertheless rather unexplored [28, 29]. Our findings show
that informing participants about data sharing and multiple uses of data in biobank ICs is still
not commonly practiced so far, despite being welcomed by biobankers, participants and the
GDPR. In that respect, it is interesting that the inclusion of data-sharing with industrial part-
ners as well as EU and non-EU countries in the IC is supported by the majority of our respon-
dents when it comes to the different roles they have in biobanking, except for researchers. Our
data hence suggests that while the importance of transparency related to data sharing in IC is
not contested, further investigation is needed on why the opinions of researchers on data shar-
ing in IC differ from other groups of respondents such as managers, administrative staff, ELSI
consultants and project managers.
The legal requirements, as well as the ethical and societal aspects of biobanking, provide an
impetus to use innovative communication formats. Viewed in this context, the IC procedure
does more than accommodate legal requirements–it offers a complex integration of new
requirements into the daily practices of biobanking, including the governance and organiza-
tional challenges this integration brings. Our data show that responses related to IC practices
did not differ significantly between countries where the GDPR applies and where it does not.
Our data suggest that there is room for improvement. On one hand, respondents indicated
that just over half of the items about the possibility that sample/data could be shared with dif-
ferent countries and stakeholders is included in the IC procedure (see Table 2). On the other
hand, many respondents think such information should be provided in ICs (see Table 3).
Findings from other quantitative and qualitative studies [5, 30, 31] that address data processing
from the perspective of participants and the public, support providing information about data
uses since concerns about data protection and potential use of personal data outside the
research context influence preferences for consent types and participants’ views of biobank-
based research.
The recent increase in data sharing, as well as demands to engage with participants in a
more interactive way within and beyond IC procedures, raises the issue of how much informa-
tion to provide to participants regarding potential recontact, feedback of results, and addi-
tional data collection. This challenge is also reflected in the apparent tension highlighted in the
data between the need for more information in the consent document, and the perceived
drawback of having long documents. Respondents’ preference for a form of web-based
dynamic consent procedure offers a potential solution, particularly since electronic consent is
explicitly mentioned as an option in the GDPR.
Re-consent and return of results
Issues of re-consent and re-contacting participants are also linked to whether and how
research findings should be returned to participants. Article 27 of The Additional Protocol to
the Convention on Human Rights and Biomedicine, concerning Biomedical Research
Data in question
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establishes a duty of care in the countries that have ratified this Council of Europe instrument,
stating:
“If research gives rise to information of relevance to the current or future health or quality
of life of research participants, this information must be offered to them. That shall be done
within a framework of health care or counselling. In communication of such information,
due care must be taken in order to protect confidentiality and to respect any wish of a par-
ticipant not to receive such information.”
The Explanatory Report exemplifies the type of information that can be relevant to offer,
mentioning “conclusions of the research or incidental information collected during the
research” [32, paragraph 131]. It goes on to state that it is the researcher who must evaluate
whether the information is of relevance to the current or future health or quality of life of
research participants, and in doing so, the researcher may seek the advice of the ethics commit-
tee (Ibid.). The term “offered” has implications for the drafting of consent forms, as it requires
that the wish of the participant to know or not to know is established prior to commencement
of the research, including a participant’s possible wish only to exercise their right to know
under certain circumstances (Ibid. and paragraph 133. In certain circumstances, the right to
know or not to know may be restricted on the basis of Article 26.1 of the Convention or in
exceptional cases on the basis of domestic law in accordance with Article 10 of the Convention,
see paragraph 134).
Although current legislation supports the return of individual research results and partici-
pants asking for them, the practice of biobanks toward this issue remains contested and ambiv-
alent. Our data show that the option least frequently selected as information that should be
provided in the IC is the ‘possibility of returning individual research results’, with 69% of par-
ticipants responding with this option and 27.6% stating that it is not essential for the IC. There
were no significant differences (X2(4) = 1.608, p = 0.807) in the views of the respondents based
on whether or not they are located in a country that has signed the Additional Protocol to the
Convention on Human Rights and Biomedicine. In each subgroup, approximately 70% of
respondents stated that the ‘possibility of returning individual research results’ should be
included in ICs. Interestingly, from 69.1% of respondents who indicated that return of results
should be included in ICs, only 18.4% of those who indicated that this item is missing in their
IC stated that it should be included.
This discrepancy raises feasibility issues and implies challenges on a structural level. A
recent study among experts in Europe [33] identified a lack of legal frameworks, professional
guidelines, and financial, organizational, and human resources as a key challenge for the
return of individual genetic results to research participants. Clarifying legal requirements and
harmonizing practices across Europe as well as cost-efficient IT-based platforms were pro-
posed as possible solutions. How far these and other institutional challenges, such as lack of
financial and time resources that were indicated as major obstacles in engaging with research
participants, may also be an issue for returning results should be investigated. However, stud-
ies showed that research participants tend to be in favour of receiving research results [5, 34,
35]. One such study [35] showed, for instance, that most participants would be comfortable
with inexpensive and easy-to-handle methods of returning information. Our findings regard-
ing return of results echo a need to improve communication between biobanks and partici-
pants, which may also benefit engagement strategies used to inform participants.
Views on re-consent and satisfaction with the IC in use differ significantly between coun-
tries where the GDPR applies and where it does not. Re-consent is deemed necessary by
respondents from GDPR countries if the data are to be used for a study in a different field
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(46.2% compared to 35.3% in non-GDPR countries). Respondents from countries where the
GDPR does not apply are in favour of re-consent if new technology requires a change in prac-
tices (29.4% vs. 10.1%). Nevertheless, 36.1% of respondents from GDPR countries view re-con-
sent as unnecessary. Questions around if and how biobanking participants should re-consent or
be re-contacted as well as if and how research findings should be returned, is debated among
ELSI scholars [33, 36]. Empirical studies have shown that most research participants want to
have a say on how their samples and data are used in research [35, 37]. Participants tend to
favour re-contact or re-consent when there are changes to the circumstances under which
research with their materials and data is performed [29, 33]. These findings reflect the chal-
lenges around collecting samples and data for unknown purposes and uses in future research.
The latter underlies biobankers’ preference for broader forms of IC [38]. This preference is also
reflected in our survey. However, qualitative investigations have shown that preferences for
broad consent are not made unconditionally by scientists as well as citizens and participants [5,
38]. In the present study, this becomes particularly apparent, demonstrated by a discrepancy
between IC practices and attitudes of biobankers. For example, around one third of respondents
stated that the information about sharing of data and samples within and outside the EU, and
the possibility for participant to be re-contacted for additional data/samples, is not included in
their current IC, but should be. So far, there is no consensus about the appropriate consent
model among scientists [38], citizens/participants [5] and ELSI scholars [39]. Furthermore,
broad consent is only allowed as an exception in cases where it is impossible to fully identify the
purpose of the data processing at the time of data collection (see Recital 33 GDPR).
Various items in the survey indicate the importance of interacting with research partici-
pants and giving them a greater say over uses of their donated samples and data. 33.3% of
respondents stated that a dynamic model should be practiced for re-use, 44.4% indicated that
re-consent is necessary when data/samples are to be used for a study in a different field, and a
majority of 62.0% of respondents think it is important to inform participants explicitly of col-
laborations with health industry at the time of recruitment to enable them to give IC about
data and sample uses in such partnerships. A possible solution for these challenges could, in
certain contexts, be found in web-based dynamic consent platforms [29, 40]. Such tools have
been described and implemented to manage re-contact and more flexible ways of re-consent-
ing, which may also support better engagement, especially for population-based biobanks.
That said, engagement should not be limited to IC practices.
Participant engagement
Engaging participants in the activities and governance of biobanks has become an important
subject in debates about biobanks’ sustainability. Various engagement exercises have been
developed and realized to explore public perceptions of and attitudes towards biobanks, and to
tighten the relationship between biobanks and participants [5, 41, 42]. Typically, their aim is to
deliberate about IC and its ethical, legal and societal implications, including the challenges
mentioned in the introduction. Despite their goal to engage participants and other members
of the public, these exercises have been criticized for their tendency to inform people about
biobanks, rather than involve them in the activities around biobanking.
Our survey data confirm this trend as they show that participant engagement has not yet
become a norm in many biobanks. Half of the respondents indicated that participants are not
involved in biobank activities. When they are involved, this mainly comprises various forms of
meetings where information is provided rather than engaged with. This result supports find-
ings and conclusions of previous studies which concluded that the involvement of participants
is practiced predominantly as upstream and one-way information provision [5, 43].
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Our findings suggest a more inclusive and transparent biobanking practice as biobanks are
seen to be playing a more active role in providing information and engaging with participants.
This assumption is supported by respondents’ views about obstacles to participant engage-
ment. Only 17.5% of respondents indicated that a lack of interest is impeding participant
involvement. Engagement activities seem to be challenged by institutional or structural condi-
tions, indicated in the survey data as too little time and resources. Whereas previous studies
focused predominantly on the challenges of engagement models, the institutional and struc-
tural embeddedness of participant engagement are rather unexplored and should be subject to
further investigation.
Public-private partnerships
Policymakers strongly encourage the development of partnerships between biobanks and the
health industry. Public-private partnerships (PPPs) are envisioned to bring new scientific dis-
coveries and benefits to society such as medical applications and jobs [18]. While survey
respondents largely acknowledge the potential scientific benefits of public-private partner-
ships, they expect PPPs to have a limited impact on economic growth, for instance through the
creation of jobs. The potential economic benefits of PPPs are not fully documented and have
been recently questioned [44]. This suggests that scientific needs and societal benefit, rather
than economic ambitions, should be the main motivators in the establishment of PPPs [45].
Our data highlight the importance of empowering participants to make informed decisions
about this issue. A majority of respondents indicated that it is important to inform participants
explicitly of collaboration with health industry partners. Accordingly, participants should, at
enrolment to studies or later, be able to base their consent on specific information about how
their data and samples might be used in such collaborations. This is in line with results from
recent studies, which show that participants are interested in having a say about the sharing of
their data [37]. This leads to the question of whether broad consent, the approach preferred by
our respondents, provides sufficient information about collaboration with industrial partners
to be legally valid, or whether more specific forms of consent are needed not only for legal
compliance, but to address the concerns and needs of research participants [46].
European citizens have been shown to be sceptical of sharing their data with the private sec-
tor [47, 48] and tend to perceive research carried out by private actors as primarily profit-ori-
ented [5]. Increased transparency may contribute to raising awareness and reflection among
participants regarding the potential advantages (and drawbacks) of establishing collaborations
with industrial actors. Transparency about the terms of the collaboration will also be central
when reconciling two groups of researchers–public and private–following different norms and
objectives [49]. Guidelines and strategies are under development aiming to help biobank
researchers establish PPPs in ways that protect the interests of the biobanks and the partici-
pants while promoting public health [50, 51].
Conclusions
As our survey shows, those who take up diverse managing roles in current biobanking see
both the necessity and the difficulty related to adapting their practices to changes in the ethical,
legal, societal and scientific landscape of biobanks. In particular, further investigations on how
transparency can be increased within IC in terms of providing more concrete information on
data sharing with industrial partners is needed. Our survey sets a stage for such investigations
as it went beyond the mere observation of these difficulties, to allow a stronger focus on struc-
tures that are and/or should be provided to ensure such integration. In this context, our find-
ings also tune in to the call for practical solutions to improve IC, especially regarding
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cooperation, support, communication, engagement and new legal requirements. The lack of
resources for such improvement–including time, financial, or human resources–is experi-
enced across European countries despite their diversity in legal and institutional situations. At
the same time, no matter how detailed and extensive a template of IC might be, biobankers
must adapt them for their own specific context. They must embed engagement activities into
their organisation’s clinical and research practices.
In that context, while it is important to continuously and systematically generate awareness
among biobankers about ELSI aspects of their work, the responses in our survey demonstrate
that identifying appropriate institutional structures is key to address the current challenges
and requirements of research. Our data show that respondents seek ethical and legal guidance
from professional information centers, turn to national and international guidance for IC or
opt for templates that follow national and international standards as the most appreciated
form of support. They particularly express the difficulty in translating these templates into
practical solutions.
Future investigations should thus focus on translational and governance structures of bio-
banking, which take the local and organisational setting of a biobank into account. Related
challenges were expressed by respondents as concerns about how to assess increasing partici-
pant involvement while maintaining biobanks’ ability to function well. The lack of translation
structures is the main obstacle to advance patient engagement and bring an institutional rou-
tine to public engagement formats. Increased transparency and new modes of IC could moti-
vate people to support collaborations with industry and open up a novel research area of
governance in biobanking. This is particularly topical given the legal, ethical and societal
requirements of the recently adopted GDPR. Our findings offer a starting point for conversa-
tions about where to place the focus of future biobank governance, and how to conceptualize
upcoming research related to the translation of new requirements into biobanks’ institutional
routines.
Limitations
Our survey was conducted online, which might exclude respondents who are less familiar or
comfortable with this method. There is also a sight asymmetry in the countries represented in
the survey with larger percentages of respondents from Italy and the Netherlands.
This survey was conducted shortly before the EU GDPR became applicable but after it was
adopted. It is therefore likely that the respondents’ organisations were already working on
compliance with the GDPR.
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